首页> 外国专利> PHARMACEUTICAL COMPOSITION CONTAINING WILD-WALNUT EXTRACT, FRACTION THEREOF, OR PHYSIOLOGICALLY ACTIVE SUBSTANCE DERIVED THEREFROM AS ACTIVE INGREDIENT, AND HAVING EFFECTS OF INHIBITING PRODUCTION OF ADVANCED GLYCATION END PRODUCTS AND DECOMPOSING ADVANCED GLYCATION END PRODUCTS

PHARMACEUTICAL COMPOSITION CONTAINING WILD-WALNUT EXTRACT, FRACTION THEREOF, OR PHYSIOLOGICALLY ACTIVE SUBSTANCE DERIVED THEREFROM AS ACTIVE INGREDIENT, AND HAVING EFFECTS OF INHIBITING PRODUCTION OF ADVANCED GLYCATION END PRODUCTS AND DECOMPOSING ADVANCED GLYCATION END PRODUCTS

机译：包含野生核桃提取物，其馏分或以其为活性成分的生理活性物质的药物组合物，具有抑制高级糖化终产物和高级糖化产物的生产的功效

页面导航

摘要
著录项
相似文献

摘要

The present invention pertains to a pharmaceutical composition containing a wild-walnut extract, a fraction thereof, or a compound isolated from the fraction. A wild-walnut extract, a fraction thereof, and a compound isolated from the fraction according to the present invention have the effects of inhibiting the production of advanced glycation end products (AGEs) and decomposing advanced glycation end products that are produced, and can thus be advantageously used in a pharmaceutical composition for preventing or treating diabetic complications, nonalcoholic steatohepatitis, or degenerative brain disease caused by advanced glycation end products (AGEs).

机译：本发明涉及含有野生核桃提取物，其级分或从级分中分离的化合物的药物组合物。本发明的野生核桃提取物，其级分和从级分中分离出的化合物具有抑制晚期糖基化终产物（AGEs）产生并分解产生的晚期糖基化终产物的作用，因此可以在药物组合物中有利地用于预防或治疗由晚期糖基化终产物（AGEs）引起的糖尿病并发症，非酒精性脂肪性肝炎或变性性脑病。

著录项

公开/公告号WO2020209690A1

专利类型
公开/公告日2020-10-15

原文格式PDF
申请/专利权人 GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION;INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY;
展开▼

申请/专利号WO2020KR04945
发明设计人 KIM SUN YEOU;KIM SEUNG HYUN;PARK SEON JU;LEE JAE HYUK;
展开▼

申请日2020-04-10
分类号A61K36/52;A61K31/085;A61K31/09;A61K31/12;A61K31/11;A61K31/343;A61P1/16;A61P25/28;A61P3/10;A23L33/105;
国家 WO
入库时间 2022-08-21 11:08:57

相似文献

专利
外文文献
中文文献